Your browser doesn't support javascript.
loading
Current Landscape on Development of Phenylalanine and Toxicity of its Metabolites - A Review.
Bose, Samrat; Mandal, Shirsendu; Khan, Rajesh; Maji, Himangshu Sekhar; Ashique, Sumel.
Afiliação
  • Bose S; Division of Pharmacology, Guru Nanak Institute of Pharmaceutical Science and Technology, 157/F, Nilgunj Road, Kolkata, 700114, West Bengal, India.
  • Mandal S; Division of Pharmacology, Guru Nanak Institute of Pharmaceutical Science and Technology, 157/F, Nilgunj Road, Kolkata, 700114, West Bengal, India.
  • Khan R; Division of Pharmacology, Guru Nanak Institute of Pharmaceutical Science and Technology, 157/F, Nilgunj Road, Kolkata, 700114, West Bengal, India.
  • Maji HS; Division of Pharmaceutical Technology, JIS University, 81, Nilgunj Road, Agarpara, Kolkata, 700109, West Bengal, India.
  • Ashique S; Department of Pharmaceutics, Bharat Institute of Technology (BIT), School of Pharmacy, Meerut, 250103, UP, India.
Curr Drug Saf ; 19(2): 208-217, 2024.
Article em En | MEDLINE | ID: mdl-36999718
ABSTRACT
Phenylalanine, an essential amino acid, is the "building block" of protein. It has a tremendous role in different aspects of metabolic events. The tyrosine pathway is the prime one and is typically used to degrade dietary phenylalanine. Phenylalanine exceeds its limit in bodily fluids and the brain when the enzyme, phenylalanine decarboxylase, phenylalanine transaminase, phenylalanine hydroxylase (PAH) or its cofactor tetrahydrobiopterin (BH4) is deficient causes phenylketonuria, schizophrenia, attentiondeficit/ hyperactivity disorder and another neuronal effect. Tyrosine, an amino acid necessary for synthesizing the pigments in melanin, is produced by its primary metabolic pathway. Deficiency/abnormality in metabolic enzymes responsible for the catabolism pathway of Phenylalanine causes an accumulation of the active intermediate metabolite, resulting in several abnormalities, such as developmental delay, tyrosinemias, alkaptonuria, albinism, hypotension and several other undesirable conditions. Dietary restriction of the amino acid(s) can be a therapeutic approach to avoid such undesirable conditions when the level of metabolic enzyme is unpredictable. After properly identifying the enzymatic level, specific pathophysiological conditions can be managed more efficiently.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fenilalanina Hidroxilase / Fenilcetonúrias Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fenilalanina Hidroxilase / Fenilcetonúrias Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article